Prenatal Down syndrome screening with maternal serum alpha-fetoprotein (AFP) and human chorionic gonadotrophin (hCG) has become common. High levels of maternal serum hCG and low levels of AFP have been associated with an increased risk of fetal Down syndrome. In this paper, we report five pregnancie
Elevated second trimester maternal serum β-HCG concentrations and subsequent adverse pregnancy outcome
✍ Scribed by Gravett, Claudia P. ;Buckmaster, John G. ;Watson, Peter T. ;Gravett, Michael G.
- Publisher
- John Wiley and Sons
- Year
- 1992
- Tongue
- English
- Weight
- 211 KB
- Volume
- 44
- Category
- Article
- ISSN
- 0148-7299
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Previous studies have found an association between elevated second trimester maternal serum α‐fetoprotein (MS‐AFP), in the absence of fetal anomalies, and adverse pregnancy outcome. We studied the association between elevated second trimester maternal serum β‐HCG, now also routinely measured by prenatal screening programs, and adverse pregnancy outcome by reviewing retrospectively the pregnancy outcomes among women with markedly elevated midtrimester β‐HCG in our prenatal screening program. Seven (0.23%) of 3,000 consecutively screened women had a serum β‐HCG above 5 MOM. Four (57%) of these 7 women had an adverse pregnancy outcome including severe preeclampsia (n = 2), abruptio placentae (n = 1), or preterm labor (n = 1). A concurrently elevated MS‐AFP was found in only one of these 4 patients. Elevated midtrimester maternal serum β‐HCG may be an independent risk factor for subsequent adverse pregnancy outcomes.
📜 SIMILAR VOLUMES
This study was undertaken to investigate the association between placenta previa and Down syndrome screening analytesÐalpha-fetoprotein (AFP) and hCGÐduring the second trimester. Measurements of maternal serum AFP and hCG concentrations were retrospectively analysed in relation to placenta previa in
Maternal serum inhibin-A concentration is a useful marker in prenatal screening for Down syndrome in the second trimester. We measured inhibin-A concentrations in 4304 pregnancies without Down syndrome between 14 and 22 weeks of pregnancy to determine the median values according to gestational age.
In a group of 26 524 control pregnancies and a group of 3728 pregnancies affected by one or more of the pregnancy complications of low birthweight, intra-uterine growth restriction (IUGR), preterm delivery and stillbirth, I have compared the relative risk of occurrence of these complications in preg